
Intensity Therapeutics, Inc. to Participate on Cancer Panel at the Wharton DC Innovations Summit

Westport, CT. – April 24, 2014 - Intensity Therapeutics, Inc. (private) announced that President and CEO Lewis H. Bender will participate in a panel discussion on Biotech Innovation in cancer at the Wharton Innovation Summit at 3:30PM on Wednesday, April 30, 2014. The Summit is sponsored by the Wharton Club and is being held at the FHI 360 Conference Center located at 1825 Connecticut Avenue NW in Washington DC. Mr. Bender will join leading cancer scientists to discuss “Disease Prevention and Cancer Therapeutics”. Mr. Bender will be available for meetings with potential collaboration partners and investors participating at the conference before and after his panel.

About Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. is a specialty pharmaceutical company whose mission is to greatly extend the lives of patients with solid tumor cancers. To have an effective cancer treatment one must destroy both the existing large observable tumors as well as the unseen micrometastases. Intensity Therapeutics is pioneering a new approach to treat cancer - in situ chemovaccination. The Company creates novel, proprietary formulations of proven chemotherapy drugs. The technology increases the drug’s tissue dispersion and cell penetration properties. These products, when injected directly into tumors result in significantly greater tumor growth inhibition and survival compared to conventionally delivered chemotherapy. In addition the technology allows for the adaptive immune system to recognize the cancer to attach the tumors and prevent disease recurrence. Further information can be found at www.intensitytherapeutics.com

Contact:

Media & Investors:

Lewis Bender
President & CEO
8 Wright Street, Suite 107
Westport, CT 06880
Tel. (203) 682-2434
Email: lbender@intensitytherapeutics.com